GPC BIOTECH AND PHARMION CORPORATION ANNOUNCE PARTNERING AGREEMENT FOR SATRAPLATIN

GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) and Pharmion Corporation (Nasdaq: PHRM) today announced that the companies have entered into a co-development and license agreement for satraplatin, the only oral platinum-based compound in advanced clinical development. Satraplatin has shown promising safety and efficacy as demonstrated by significant improvement in progression-free survival (PFS) in a randomized study of first-line treatment of patients with hormone-refractory prostate cancer (HRPC) and is currently the subject of a Phase 3 registrational trial as second-line chemotherapy treatment for patients with HRPC.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-20-2005/0004236818&EDATE=)